title: [The effects of 40 mg atorvastatin on serum lipids, inflammatory markers and clinical events in ACS patients post PCI].
abstract: OBJECTIVE
  To assess the safety and effects of 40 mg atorvastatin on serum lipids, inflammatory markers and clinical events in ACS patients post PCI.
  
  
  METHODS
  A total of 92 patients with ACS post successful PCI were randomly divided into atorvastatin 10 mg/d (group A) and atorvastatin 40 mg/d (group B) on top of the standard medical therapy. Blood were taken at baseline, 4, 12 and 24 weeks for serum alanine aminotransferase (ALT), lipids, high-sensitive C-reactive protein (hs-CRP) and matrix metalloprotease-9 (MMP-9) measurements. The major adverse cardiac events (MACE) were also observed.
  
  
  RESULTS
  There was no significant difference in medication withdrawn (2 vs. 3 cases) due to increased ALT (3 times higher than normal) and incidence of MACE (5 vs. 7 cases) between the groups. TC and LDL were significantly reduced in both groups 4 weeks and thereafter post medication compared to pre-treatment (P < 0.05) and the reduction was more significant in group B than that in group A at 24 weeks post medication (P < 0.05) while TG and HDL remained unchanged. hs-CRP was significantly reduced at 12 and 24 weeks in both groups compared to baseline and the reduction was more significant in group B than that in group A at 24 weeks. MMP-9 was significantly reduced in both groups 4 weeks and thereafter post medication compared to pre-treatment (P < 0.05) and the reduction was more significant in group B than that in group A at 12 weeks post medication (P < 0.05).
  
  
  CONCLUSIONS
  Both atorvastatin doses significantly reduced TC, LDL, hs-CRP and MMP-9 in ACS patients post PCI and the reduction was more significant in high dose atorvastatin group at 24 weeks while the MACE and drug withdraw rates were similar between the groups.
authors.affiliation: Department of Cardiology, The Second Clinical Hospital of Jinan University (Shenzhen People's Hospital), Shenzhen 518026, China. dsh266@medmail.com.cn
authors.forename: Shao-hong
authors.initials: SH
authors.lastname: Dong
authors.forename: Jun-min
authors.initials: JM
authors.lastname: Wen
authors.forename: Lin-jie
authors.initials: LJ
authors.lastname: Luo
authors.forename: Ke-qi
authors.initials: KQ
authors.lastname: Chen
authors.forename: Xin-jian
authors.initials: XJ
authors.lastname: Liang
authors.forename: Yi-fu
authors.initials: YF
authors.lastname: Li
authors.forename: Hua-dong
authors.initials: HD
authors.lastname: Liu
authors.forename: Huan-zhan
authors.initials: HZ
authors.lastname: Chen
authors.forename: Zhi-xin
authors.initials: ZX
authors.lastname: Huang
authors.forename: Xin
authors.initials: X
authors.lastname: Jiang
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood* / Q000188:drug therapy*; D000410:Alanine Transaminase / Q000097:blood; D015906:Angioplasty, Balloon, Coronary; D000069059:Atorvastatin; D002097:C-Reactive Protein / Q000378:metabolism; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D020780:Matrix Metalloproteinase 9 / Q000097:blood; D011446:Prospective Studies; D011758:Pyrroles / Q000627:therapeutic use*
chemical_list: D006538:Heptanoic Acids; D000960:Hypolipidemic Agents; D011758:Pyrroles; D002097:C-Reactive Protein; D000069059:Atorvastatin; D000410:Alanine Transaminase; D020780:Matrix Metalloproteinase 9